Unlike many cancers, younger patients (in their 20s-30s) with low-grade serous ovarian cancer have a worse prognosis than older patients. This is because they are less likely to carry a KRAS mutation, making them less responsive to highly effective targeted therapies.
The landmark GY019 trial confirmed that letrozole alone is inferior to the standard of chemotherapy followed by letrozole maintenance. This was a surprising result for a chemo-resistant tumor, solidifying the need for chemotherapy in the adjuvant setting despite its limited effectiveness.
This cancer is a "low-shedding" tumor, making circulating tumor DNA (ctDNA) difficult to detect. A key study found only 32% of patients with measurable disease had detectable ctDNA, and the concordance for KRAS status with tumor sequencing was only 44%, mandating tissue-based testing.
The RAMP-201 trial showed the combination of Avutometinib and Defactinib achieved a 25% response rate even in patients who had progressed on or were intolerant of prior single-agent MEK inhibitors. This establishes the doublet as an effective subsequent line of therapy in a resistant population.
While initial response rates are similar between the Avutometinib/Defactinib doublet and single-agent Trametinib, the doublet provides double the progression-free survival (PFS). Its remarkable duration of response (over 30 months) indicates superior long-term disease control.
The doublet's unique dosing schedule (twice-weekly pills for three weeks, then one week off) is crucial for its long-term success. This "recovery week" per cycle is thought to reduce cumulative toxicity, allowing patients to stay on this highly effective therapy for extended periods.